Down-regulation of cFLIP following reovirus infection sensitizes human ovarian cancer cells to TRAIL-induced apoptosis

被引:19
作者
Clarke, Penny
Tyler, Kenneth L.
机构
[1] Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA
[2] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO 80220 USA
[3] Denver Vet Affairs Med Ctr, Dept Microbiol, Denver, CO 80220 USA
[4] Denver Vet Affairs Med Ctr, Dept Immunol, Denver, CO 80220 USA
关键词
reovirus; TRAIL; cFLIP; OVCAR3; apoptosis;
D O I
10.1007/s10495-006-0528-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) shows promise as a chemotherapeutic agent. However, many human cancer cells are resistant to killing by TRAIL. We have previously demonstrated that reovirus infection increases the susceptibility of human lung (H157) and breast (ZR75-1) cancer cell lines to TRAIL-induced apoptosis. We now show that reovirus also increases the susceptibility of human ovarian cancer cell lines (OVCAR3, PA-1 and SKOV-3) to TRAIL-induced apoptosis. Reovirus-induced increases in susceptibility of OVCAR3 cells to TRAIL require virus uncoating and involve increased activation of caspases 3 and 8. Reovirus infection results in the down-regulation of cFLIP (cellular FLICE inhibitory protein) in OVCAR3 cells. Down-regulation of cFLIP following treatment of OVCAR3 cells with antisense cFLIP oligonucleotides or PI3 kinase inhibition also increases the susceptibility of OVCAR3 cells to TRAIL-induced apoptosis. Finally, over-expression of cFLIP blocks reovirus-induced sensitization of OVCAR3 cells to TRAIL-induced apoptosis. The combination of reovirus and TRAIL thus represents a promising new therapeutic approach for the treatment of ovarian cancer.
引用
收藏
页码:211 / 223
页数:13
相关论文
共 69 条
[1]   Reovirus therapy of lymphoid malignancies [J].
Alain, T ;
Hirasawa, K ;
Pon, KJ ;
Nishikawa, SG ;
Urbanski, SJ ;
Auer, Y ;
Luider, J ;
Martin, A ;
Johnston, RN ;
Janowska-Wieczorek, A ;
Lee, PWK ;
Kossakowska, AE .
BLOOD, 2002, 100 (12) :4146-4153
[2]  
Asakuma J, 2003, CANCER RES, V63, P1365
[3]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[4]   Death receptors: Signaling and modulation [J].
Ashkenazi, A ;
Dixit, VM .
SCIENCE, 1998, 281 (5381) :1305-1308
[5]   Activation of caspases-8 and-10 by FLIPL [J].
Boatright, KM ;
Deis, C ;
Denault, JB ;
Sutherlin, DP ;
Salvesen, GS .
BIOCHEMICAL JOURNAL, 2004, 382 (02) :651-657
[6]   A unified model for apical caspase activation [J].
Boatright, KM ;
Renatus, M ;
Scott, FL ;
Sperandio, S ;
Shin, H ;
Pedersen, IM ;
Ricci, JE ;
Edris, WA ;
Sutherlin, DP ;
Green, DR ;
Salvesen, GS .
MOLECULAR CELL, 2003, 11 (02) :529-541
[7]   TRAIL receptor-2 signals apoptosis through FADD and caspase-8 [J].
Bodmer, JL ;
Holler, N ;
Reynard, S ;
Vinciguerra, P ;
Schneider, P ;
Juo, P ;
Blenis, J ;
Tschopp, J .
NATURE CELL BIOLOGY, 2000, 2 (04) :241-243
[8]   Prostate-apoptosis-response-gene-4 increases sensitivity to TRAIL-induced apoptosis [J].
Boehrer, S ;
Nowak, D ;
Puccetti, E ;
Ruthardt, M ;
Sattler, N ;
Trepohl, B ;
Schneider, B ;
Hoelzer, D ;
Mitrou, PS ;
Chow, KU .
LEUKEMIA RESEARCH, 2006, 30 (05) :597-605
[9]  
Bonavida B, 1999, INT J ONCOL, V15, P793
[10]   Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-κB activation and cFLIPL up-regulation [J].
Bortul, R ;
Tazzari, PL ;
Cappellini, A ;
Tabellini, G ;
Billi, AM ;
Bareggi, R ;
Manzoli, L ;
Cocco, L ;
Martelli, AM .
LEUKEMIA, 2003, 17 (02) :379-389